← Human Trials & Peer-Reviewed Studies
Fully closed-loop control with ultra-rapid versus standard insulin lispro: A randomised crossover study simulating missed meal boluses
Plain-language guide to PMID 40815068 (2025): open-label randomized controlled trial study of Insulin Lispro in 18 adults.
Key Facts
- PMID
- 40815068
- Journal
- Diabetic medicine : a journal of the British Diabetic Association
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Thabit H et al. (6 authors)
- DOI
- 10.1111/dme.70122
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Lispro.
Who Took Part
The abstract describes 18 adults taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
In this open-label, randomised crossover trial, 18 adults with type 1 diabetes using insulin pump therapy [12 females, age 39.1 (14.2) yrs., HbA1c 57.9 (8.7) mmol/mol] completed two 8-h inpatient sessions (09:00 to 17:00 h).
Participants received a standardised meal at 11:00 h without a meal bolus.
How the Study Was Run
The design is described as randomized, open-label and crossover.
The adults were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.
Being open-label, the Insulin Lispro study did not mask who received what.
Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.
Glucose levels were managed using the CamAPS FX closed-loop system with either URIL or IL, in random order.
What Was Measured
PubMed files the paper under topics including Insulin Lispro, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin Infusion Systems, Blood Glucose, Meals and Glycated Hemoglobin.
The authors tagged it with the keywords insulin analogues, insulin delivery and type 1 diabetes.
What This Means in Plain Language
The paper is a randomized, open-label and crossover study of Insulin Lispro in 18 adults.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.
More context: the Insulin Lispro compound page, all human trials.
Our Notes on the Compound
Insulin Lispro: A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.